Protective Effect of Saponins from Panax notoginseng against Doxorubicin-Induced Cardiotoxicity in Mice

 

 Buy Article Permissions and Reprints

Abstract

The dried rhizome of Panax notoginseng is a traditional Chinese herb extensively used for treatment of cardiovascular diseases and other ailments. Panax notoginseng saponins (PNS) are known as the major pharmacologically active constituents. The purpose of this study was to investigate the cardioprotective effects of PNS against doxorubicin-induced cardiotoxicity and its possible influence on the anti-tumor activity of doxorubicin. Five groups of ICR mice were treated with saline (control group), doxorubicin alone (20 mg/kg i. p.), PNS alone, doxorubicin pretreated with PNS (100 mg/kg i. g. for 5 consecutive days) or amifostine (single dose of 200 mg/kg i. v., used as positive control). After 72 h of doxorubicin treatment, cardiac function, serum levels of lactate dehydrogenase (LDH), creatine kinase (CK) and creatine kinase isoenzyme (CK-MB) and activities of antioxidant enzymes in heart tissue were measured. Pretreatment with PNS significantly protected the mice from DOX-induced cardiotoxicity as evidenced from improved ventricular contractile function, lower levels of serum LDH, CK and CK-MB, minimal morphological changes in hearts, and normalization of myocardial superoxide dismutase, glutathione peroxidase and catalase activities. Additionally, in vitro cytotoxic studies demonstrated that PNS did not compromise the inhibitory effect of doxorubicin on the proliferation of cancer cells. These results imply the potentially clinical application of PNS to overcome the negative side effects of doxorubicin.

Abbreviations

CAT:catalase

CK:creatine kinase

CK-MB:creatine kinase isoenzyme

DOX:doxorubicin

±dP/dt:first derivative of left ventricular pressure over time

GSH-Px:glutathione peroxidase

HR:heart rate

LDH:lactate dehydrogenase

LVEDP:left ventricular end-diastolic pressure

LVSP:left ventricular systolic pressure

PNS:Panax notoginseng saponins

SOD:superoxide dismutase

References

• 1 Ng T B. Pharmacological activity of sanchi ginseng (Panax notoginseng).  J Pharm Pharmacol. 2006;  58 1007-19
  CrossrefPubMedGoogle Scholar
• 2 Ferrans V J. Overview of cardiac pathology in relation to anthracycline cardiotoxicity.  Cancer Treat Rep. 1978;  62 955-61
  PubMedGoogle Scholar
• 3 Xu M F, Tang P L, Qian Z M, Ashraf M. Effects by doxorubicin on the myocardium are mediated by oxygen free radicals.  Life Sci. 2001;  68 889-901
  CrossrefPubMedGoogle Scholar
• 4 Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, Kotamraju S. Doxorubicin-induced apoptosis: implications in cardiotoxicity.  Mol Cell Biochem. 2002;  234 - 235 119-24
  CrossrefPubMedGoogle Scholar
• 5 Pessah I N. Calcium release channel of sarcoplasmic reticulum: an important target for doxorubicin-mediated cardiotoxicity.  Adv Exp Med Biol. 1992;  311 409-10
  PubMedGoogle Scholar
• 6 Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, Schlattner U. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics.  J Mol Cell Cardiol. 2006;  41 389-405
  CrossrefPubMedGoogle Scholar
• 7 Li L, Zhang J L, Sheng Y X, Guo D A, Wang Q, Guo H Z. Simultaneous quantification of six major active saponins of Panax notoginseng by high-performance liquid chromatography-UV method.  J Pharm Biomed Anal. 2005;  38 45-51
  CrossrefPubMedGoogle Scholar
• 8 Liu X, Chua C C, Gao J, Chen Z, Landy C L, Hamdy R. et al . Pifithrin-alpha protects against doxorubicin-induced apoptosis and acute cardiotoxicity in mice.  Am J Physiol Heart Circ Physiol. 2004;  286 H933-9
  PubMedGoogle Scholar
• 9 Oyanagui Y. Reevaluation of assay methods and establishment of kit for superoxide dismutase activity.  Anal Biochem. 1984;  142 290-6
  CrossrefPubMedGoogle Scholar
• 10 Goth L. A simple method for determination of serum catalase activity and revision of reference range.  Clin Chim Acta. 1991;  196 143-51
  CrossrefPubMedGoogle Scholar
• 11 Redegeld F A, van Opstal M A, Houdkamp E, van Bennekom W P. Determination of glutathione in biological material by flow-injection analysis using an enzymatic recycling reaction.  Anal Biochem. 1988;  174 489-95
  CrossrefPubMedGoogle Scholar
• 12 El-Demerdash E, Ali A A, Sayed-Ahmed M M, Osman A M. New aspects in probucol cardioprotection against doxorubicin-induced cardiotoxicity.  Cancer Chemother Pharmacol. 2003;  52 411-6
  CrossrefPubMedGoogle Scholar
• 13 Liu X, Chen Z, Chua C C, Ma Y S, Youngberg G A, Hamdy R. et al . Melatonin as an effective protector against doxorubicin-induced cardiotoxicity.  Am J Physiol Heart Circ Physiol. 2002;  283 H254-63
  PubMedGoogle Scholar
• 14 Berthiaume J M, Oliveira P J, Fariss M W, Wallace K B. Dietary vitamin E decreases doxorubicin-induced oxidative stress without preventing mitochondrial dysfunction.  Cardiovasc Toxicol. 2005;  5 257-67
  CrossrefPubMedGoogle Scholar
• 15 Fadillioglu E, Oztas E, Erdogan H, Yagmurca M, Sogut S, Ucar M. et al . Protective effects of caffeic acid phenethyl ester on doxorubicin-induced cardiotoxicity in rats.  J Appl Toxicol. 2004;  24 47-52
  CrossrefPubMedGoogle Scholar
• 16 Sadzuka Y, Sugiyama T, Shimoi K, Kinae N, Hirota S. Protective effect of flavonoids on doxorubicin-induced cardiotoxicity.  Toxicol Lett. 1997;  92 1-7
  CrossrefPubMedGoogle Scholar
• 17 Jagetia G C, Reddy T K, Malagi K J, Nayak B S, Naidu M B, Ravikiran P B. et al . Antarth, a polyherbal preparation protects against the doxorubicin-induced toxicity without compromising its antineoplastic activity.  Phytother Res. 2005;  19 772-8
  CrossrefPubMedGoogle Scholar
• 18 Mohan I K, Kumar K V, Naidu M U, Khan M, Sundaram C. Protective effect of CardiPro against doxorubicin-induced cardiotoxicity in mice.  Phytomedicine. 2006;  13 222-9
  CrossrefPubMedGoogle Scholar
• 19 Speyer J L, Green M D, Kramer E, Rey M, Sanger J, Ward C. et al . Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer.  N Engl J Med. 1988;  319 745-52
  PubMedGoogle Scholar
• 20 Herman E H, el-Hage A, Ferrans V J. Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats.  Toxicol Appl Pharmacol. 1988;  92 42-53
  CrossrefPubMedGoogle Scholar
• 21 Bast A, Kaiserova H, den Hartog G J, Haenen G R, van der Vijgh W J. Protectors against doxorubicin-induced cardiotoxicity: Flavonoids.  Cell Biol Toxicol. 2007;  23 39-47
  CrossrefPubMedGoogle Scholar
• 22 Jahnukainen K, Jahnukainen T, Salmi T T, Svechnikov K, Eksborg S, Soder O. Amifostine protects against early but not late toxic effects of doxorubicin in infant rats.  Cancer Res. 2001;  61 6423-7
  PubMedGoogle Scholar
• 23 Catino A, Crucitta E, Latorre A, Sambiasi D, Calabrese P, Lorusso V. Amifostine as chemoprotectant in metastatic breast cancer patients treated with doxorubicin.  Oncol Rep. 2003;  10 163-7
  PubMedGoogle Scholar
• 24 Nazeyrollas P, Frances C, Prevost A, Costa B, Lorenzato M, Kantelip J P. et al . Efficiency of amifostine as a protection against doxorubicin toxicity in rats during a 12-day treatment.  Anticancer Res. 2003;  23 405-9
  PubMedGoogle Scholar
• 25 Dragojevic-Simic V M, Dobric S L, Bokonjic D R, Vucinic Z M, Sinovec S M, Jacevic V M. et al . Amifostine protection against doxorubicin cardiotoxicity in rats.  Anticancer Drugs. 2004;  15 169-78
  PubMedGoogle Scholar
• 26 Doroshow J H, Locker G Y, Myers C E. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin.  J Clin Invest. 1980;  65 128-35
  PubMedGoogle Scholar
• 27 Li X, Chen J X, Sun J J. Protective effects of Panax notoginseng saponins on experimental myocardial injury induced by ischemia and reperfusion in rat.  Zhongguo Yao Li Xue Bao. 1990;  11 26-9
  PubMedGoogle Scholar
• 28 Gao B Y, Li X J, Liu L, Zhang B H. Effect of panaxatriol saponins isolated from Panax notoginseng (PTS) on myocardial ischemic arrhythmia in mice and rats.  Yao Xue Xue Bao. 1992;  27 641-4
  PubMedGoogle Scholar
• 29 Dan H X, Zhang B H, Xie S R, Yao J A, Jia J N. Effects of panaxadiol saponins isolated from Panax notoginseng on intracellular and extracellular calcium.  Zhongguo Yao Li Xue Bao. 1993;  14 (Suppl) S22-5
  PubMedGoogle Scholar
• 30 Xiong Z G, Sun J J. Effects of Panax notoginseng saponin Rb1 and Rg1 on myocardial action potential and slow inward current.  Zhongguo Yao Li Xue Bao. 1989;  10 520-2
  PubMedGoogle Scholar
• 31 Asayama J, Tanaka T, Tatsumi T, Nakagawa C, Kobara M, Matoba S. et al . Effect of doxorubicin on postrest contraction in isolated rat hearts.  J Cardiovasc Pharmacol. 1995;  26 693-7
  PubMedGoogle Scholar
• 32 Yang Z G, Sun H X, Ye Y P. Ginsenoside Rd from Panax notoginseng is cytotoxic towards HeLa cancer cells and induces apoptosis.  Chem Biodivers. 2006;  3 187-97
  CrossrefPubMedGoogle Scholar
• 33 Wang C Z, Luo X, Zhang B, Song W X, Ni M, Mehendale S. et al . Notoginseng enhances anti-cancer effect of 5-fluorouracil on human colorectal cancer cells.  Cancer Chemother Pharmacol. 2007;  60 69-79
  CrossrefPubMedGoogle Scholar

Prof. Yi-yu Cheng

Pharmaceutical Informatics Institute

College of Pharmaceutical Sciences

Zijin’gang Campus

Zhejiang University

Hangzhou 310058

People’s Republic of China

Phone: +86-571-8795-1138

Fax: +86-57-8795-1138

Email: Chengyy@zju.edu.cn

• Supplementary Material